SAGE Therapeutics Inc (NASDAQ:SAGE) CEO Jeffrey M. Jonas sold 210,247 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the sale, the chief executive officer now owns 211,473 shares in the company, valued at approximately $33,296,423.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
SAGE Therapeutics Inc (SAGE) traded up $10.49 during trading hours on Friday, reaching $165.89. The company had a trading volume of 728,668 shares, compared to its average volume of 1,274,878. SAGE Therapeutics Inc has a 12-month low of $44.55 and a 12-month high of $173.36. The firm has a market capitalization of $6,379.80, a P/E ratio of -24.15 and a beta of 3.03.
SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.01. The firm’s revenue was up .0% on a year-over-year basis. analysts expect that SAGE Therapeutics Inc will post -7.42 EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in SAGE Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 138 shares during the last quarter. Hershey Trust Co. bought a new stake in SAGE Therapeutics during the third quarter worth approximately $118,000. Oppenheimer Asset Management Inc. boosted its position in SAGE Therapeutics by 412.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,565 shares during the period. Bessemer Group Inc. bought a new stake in SAGE Therapeutics during the third quarter worth approximately $141,000. Finally, Canada Pension Plan Investment Board bought a new stake in SAGE Therapeutics during the second quarter worth approximately $175,000. Hedge funds and other institutional investors own 95.33% of the company’s stock.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.